论文部分内容阅读
目的探讨补体反应基因-32(RGC-32)在结肠癌组织中的表达情况,并分析其临床意义。方法选取2012年12月至2015年12月沈阳市第九人民医院收治的结肠癌患者80例为研究对象,癌组织标本均采用免疫组化SP法检测RGC-32表达,观察不同肿瘤分化程度、淋巴结转移及不同TNM分期RGC-32的阳性表达情况。结果高中分化者RGC-32乘积积分及RGC-32阳性率均低于低分化者,差异有统计学意义(P<0.05);存在淋巴结转移者RGC-32乘积积分及RGC-32阳性率均低于无淋巴结转移者,差异有统计学意义(P<0.05);TNM分期Ⅰ+Ⅱ期者RGC-32乘积积分及RGC-32阳性率低于TNM分期Ⅲ+Ⅳ期者,差异有统计学意义(P<0.05)。结论 RGC-32可作为结肠癌患者预后的预测指标及靶向治疗新突破。
Objective To investigate the expression of complement reactive gene -32 (RGC-32) in colon cancer and to analyze its clinical significance. Methods Eighty patients with colon cancer admitted to the Ninth People’s Hospital of Shenyang from December 2012 to December 2015 were enrolled in this study. The expression of RGC-32 was detected by immunohistochemical SP method in cancer samples. The differentiation, Lymph node metastasis and different TNM staging RGC-32 positive expression. Results The positive rates of RGC-32 product and RGC-32 in high school students were significantly lower than those in poorly-differentiated patients (P <0.05). The positive rates of RGC-32 product in patients with lymph node metastasis and those with RGC-32 There was significant difference between the two groups (P <0.05). The positive rates of RGC-32 product and RGC-32 in TNM stage Ⅰ + Ⅱ stage were lower than those in stage Ⅲ + Ⅳ stage TNM stage, the difference was statistically significant (P <0.05). Conclusion RGC-32 can be used as a predictor of prognosis and a new breakthrough in targeted therapy in patients with colon cancer.